Chimeric Therapeutics to Consolidate Shares and Equity Securities

Chimeric Therapeutics Ltd. ( (AU:CHM) ) has issued an announcement.

Chimeric Therapeutics Limited has announced a security consolidation affecting its ordinary fully paid shares, several classes of options with various expiry dates and exercise prices, and performance rights. The consolidation will see trading in the post-consolidation securities commence on a deferred settlement basis from 22 April 2026, with a record date of 23 April 2026 and an issue date of 30 April 2026, signalling a restructuring of the company’s capital that may influence liquidity and pricing dynamics for existing security holders.

The consolidation is subject to required approvals, including security holder consent and potentially other external conditions that must be satisfied before the timetable’s commencement. By reorganising its capital structure across all listed equity instruments, Chimeric is positioning itself for a more streamlined share base, which can improve market perception, reduce administrative complexity, and potentially enhance the attractiveness of its securities to institutional and retail investors.

The most recent analyst rating on (AU:CHM) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Chimeric Therapeutics Ltd. stock, see the AU:CHM Stock Forecast page.

More about Chimeric Therapeutics Ltd.

Chimeric Therapeutics Limited is an Australian biotechnology company listed on the ASX under the code CHM. The company is focused on developing therapeutic products and related securities, including ordinary shares, options, and performance rights, aimed at investors in the life sciences and biotech sector.

Technical Sentiment Signal: Sell

Current Market Cap: A$8.84M

For an in-depth examination of CHM stock, go to TipRanks’ Overview page.